Assertio Holdings, Inc.
Assertio Holdings is a pharmaceutical company that markets differentiated products primarily in oncology and specialty care. Its lead product is ROLVEDON, a long-acting G-CSF for febrile neutropenia in cancer patients, acquired via the July 2023 Spectrum merger. The company also markets Sympazan (clobazam for seizures), INDOCIN (indomethacin for rheumatologic and pain indications), SPRIX (ketorolac nasal spray for acute pain), and CAMBIA (diclofenac for migraine). Assertio distributes through three major U.S. wholesalers and does not manufacture; it relies on contract manufacturers in multiple countries and third-party suppliers for active pharmaceutical ingredients.
Summary from 10-K filed 2026-03-16
Frequently asked questions
What is Assertio Holdings, Inc.'s CIK number?
Assertio Holdings, Inc.'s SEC CIK number is 0001808665 (1808665). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Assertio Holdings, Inc.'s SEC filings?
All of Assertio Holdings, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.